SpectrumX, a UK-based healthcare and pharmaceutical company, said it is partnering with a UK-based contract manufacturing group with global reach to advance the production of its anti-pathogenic medicine for use in its planned Phase I clinical trials. SpectrumX said this group has many years of experience in MHRA-compliant medicine production.

SpectrumX plans to use its partner’s good manufacturing practice (GMP)-certified facility to produce SPX-001, the medical product based on the SPC-069 drug substance, for clinical trials. SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties. SpectrumX will continue to produce its proprietary HOCl chemistry, essential to SPX-001’s success, at its production facility in Knutsford.

The Medicines and Healthcare products Regulatory Agency (MHRA) requires that drugs for trials must be manufactured in a GMP approved facility. SpectrumX’s chosen partner is a leader in contract drug development and manufacturing services and possesses the expertise required to streamline the roll-out of the production of the SPX-001 investigational medicinal product for use in SpectrumX’s clinical trials program, according to the company. By partnering in this way, SpectrumX will be well-prepared for an upcoming MHRA scientific advice meeting.

“I am pleased to announce our partnership with an established leader in the manufacture and production of drugs for clinical trials,” said Damien Hancox, CEO of SpectrumX. “This partnership will hasten the process of getting SPX-001, our SPC-069-based medical product, to clinical trials and may provide us an opportunity to commercialize our lead pharmaceutical product in a shorter time frame.”